The results showed that the risk of NSCLC metastasis was higher when plasma versican ≥ 1632.68 pg/ml, suggesting that in the advanced stage of lung cancer, versican secreted by lung cancer will enter the peripheral blood in large quantities, and the detection of plasma versican protein will have more clinical value. This evidence concerns the gene VCAN and non-small cell lung carcinoma.